Commentary: Occult prostate cancer - Imposter or the real deal?

International Journal of Epidemiology

Volumn 36, Issue 2, 2007, Pages 281-282

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Prostate cancer pathology; Prostate neoplasm

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

AUTOPSY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SCREENING; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; MALE; NOTE; OCCULT CANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AUTOPSY; HUMANS; INCIDENTAL FINDINGS; MALE; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 34447550563     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym051     Document Type: Note

References (8)

1. Rich AR. On the frequency of occurrence of occult carcinoma of the prostate. Journal of Urology 1935;33:215-23. (Reprinted Int J Epidemiol. 2007;36:274-77).
2. Franks LM. Latency and progression in tumors: The natural history of prostatic cancer. Lancet 1956;2:1037-39.
3. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in you male patients. J Urol 1993;150:379-85.
4. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
5. Gleason DF, Mellinger GT. Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974; 111:58-64.
6. McNeal JE. Cancer volume and site of origin of adenocarcinoma of the prostate: Relationship to local and distant spread. Hum Pathol 1992;23:258-66.
7. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection: The significance of margins designated as negative, closely approaching and positive. Am J Surg Pathol 1990;14:626-32.
8. Draisma G. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.